Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | TPMT | P51580 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30310598 | 1.00 | ERN1 (0.40) | ERN1ALDH1A1KDM4EGAATPMT | |
| SCHEMBL1186103 | 0.81 | ERN1 (0.52) | ERN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL29951095 | 0.81 | ERN1 (0.52) | ERN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL6413771 | 0.81 | ERN1 (0.53) | ERN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL31551028 | 0.81 | ERN1 (0.53) | ERN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL3759267 | 0.80 | ALDH1A1 (0.44) | ALDH1A1KDM4EGAATPMTTDP1 | |
| SCHEMBL31538431 | 0.79 | ERN1 (0.49) | ERN1ALDH1A1KDM4EGAATSHR | |
| SCHEMBL1747997 | 0.79 | ERN1 (0.41) | ERN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL14292700 | 0.79 | ERN1 (0.41) | ERN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL6103512 | 0.78 | ERN1 (0.42) | ERN1CA1CA2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| EP-4161902-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-2774914-B1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | UNIV NANJING MEDICAL (CN) | 2017-12-06 | — | — | EP | disclosed |
| US-9481636-B2 | N-benzylaniline derivative and uses thereof | NANJING MEDICAL UNIVERSITY (CN) | 2016-11-01 | — | — | US | disclosed |
| US-20140303248-A1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | Neurodawn Pharmaceutical Co., Ltd. (CN) | 2014-10-09 | — | — | US | disclosed |
| US-20070179060-A1 | 6-(Poly-substituted aryl)-4-aminopicolinates and their use as herbicides | CORTEVA AGRISCIENCE LLC | 2007-08-02 | — | — | US | disclosed |
| WO-2007082098-A2 | 6-(POLY-SUBSTITUTED ARYL)-4-AMINOPICOLINATES AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2007-07-19 | — | — | WO | disclosed |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | GALENEA CORPORATION | 2006-09-14 | — | — | US | disclosed |
| WO-2006081332-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | EPIX DELAWARE, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| EP-0112620-B1 | 5-(SUBSTITUTED PHENYL) HYDANTOINS | PFIZER INC. (US) | 1986-12-30 | — | — | EP | disclosed |
| EP-0112620-A1 | 5-(Substituted phenyl) hydantoins | PFIZER INC. (US) | 1984-07-04 | — | — | EP | disclosed |
| US-4448971-A | Hypoglycemic 5-phenyl-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1984-05-15 | — | — | US | disclosed |
| US-4407811-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1983-10-04 | — | — | US | disclosed |
| US-4399296-A | TRIMETHYLSILYL CYANOHYDRIN INTERMEDIATES | PFIZER INC. (US) | 1983-08-16 | — | — | US | disclosed |
| US-4367234-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1983-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179060-A1 | 6-(Poly-substituted aryl)-4-aminopicolinates and their use as herbicides | AAAS, DDT, AADAC | ERN1 4793/4885ALDH1A1 1065/4885KDM4E 672/4885 |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | HTR6, HTR2A, HTR3B | ERN1 4404/4885ALDH1A1 1488/4885KDM4E 1616/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | ERN1 1085/4885ALDH1A1 1863/4885KDM4E 3122/4885 |
| US-20140303248-A1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | NLN, INA, TRPV1 | ERN1 1346/4885ALDH1A1 1015/4885KDM4E 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.